DR. MITCHELL S. STEINER, MD
Urology at Nonconnah Blvd, Memphis, TN

2005008, Apr 14, 2005

Jan 20, 2004

10/760152

James Dalton - Upper Arlington OH, US
Duane Miller - Germantown TN, US
Mitchell Steiner - Germantown TN, US
Karen Veverka - Cordova TN, US

A61K031/66, A61K031/32, A61K031/165, A61K031/277

514114000, 514493000, 514522000, 514617000, 514618000, 514616000

This invention relates to the prevention and treatment of breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of a) treating a subject suffering from breast cancer; b) preventing, suppressing, inhibiting or reducing the incidence of breast cancer in a subject; c) delaying the progression of breast cancer in a subject suffering from breast cancer; d) preventing the recurrence of breast cancer in a subject; e) treating the recurrence of breast cancer in a subject suffering from breast cancer; and/or f) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer, by administering to the subject a therapeutically effective amount of an Androgen Receptor Antagonist and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug or any combination thereof, as described herein.

6413535, Jul 2, 2002

Sep 12, 2000

09/660197

Mitchell S. Steiner - Germantown TN
Sharan Raghow - Collierville TN

The University of Tennessee Research Corporation - Knoxville TN

A61F 1300

424422, 424434, 424489, 424464, 424433, 424452, 514944, 514965, 514938

This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of preventing prostate carcinogenesis comprising the steps of administering to a human subject having a precancerous precursor of prostate adenocarcinoma, a pharmaceutical preparation comprising a chemopreventive agent to prevent, prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

6632447, Oct 14, 2003

Nov 8, 2000

09/707766

Mitchell S. Steiner - Germantown TN
Sharan Raghow - Collierville TN

The University of Tennessee Research Corporation - Knoxville TN

A61F 1300

424434, 424489, 424464, 424433, 424452, 514965, 514938, 514648, 514651

This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent and analogs and metabolites thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibit prostate carcinogenesis; and treats prostate cancer.

2005008, Apr 14, 2005

Oct 14, 2003

10/683161

James Dalton - Upper Arlington OH, US
Duane Miller - Germantown TN, US
Mitchell Steiner - Germantown TN, US
Karen Veverka - Cordova TN, US

A61K031/66, A61K031/32, A61K031/21, A61K031/165, A61K031/195, A61K031/277

514114000, 514563000, 514493000, 514522000, 514514000, 514616000, 514618000, 514620000, 514621000

The present invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of an Androgen Decline in Aging Male (ADAM)-associated condition in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof. The present invention further provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, benign prostate hyperplasia or prostate cancer due to ADAM in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, crystal, or any combination thereof.

7705182, Apr 27, 2010

Feb 24, 2003

10/371155

James T. Dalton - Upper Arlington OH, US
Duane D. Miller - Germantown TN, US
Mitchell S. Steiner - Germantown TN, US
Karen A. Veverka - Cordova TN, US
Dong Jin Hwang - Memphis TN, US
Jiyun Chen - Columbus OH, US

University of Tennessee Research Foundation - Knoxville TN

C07C 233/05, A61K 31/16

564175, 564155, 558417, 514616, 514617, 514522, 514524

This invention provides androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; and/or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

2006027, Nov 30, 2006

May 31, 2005

11/140255

Mitchell Steiner - Germantown TN, US
Sharan Raghow - Collierville TN, US

A61K 31/56, A61K 31/453, A61K 31/138

514169000, 514651000, 514320000

This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent, for example raloxifene, or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, ester, or N-oxide, or mixtures thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibits prostate carcinogenesis and treats prostate cancer.

2011023, Sep 29, 2011

Apr 8, 2011

13/082830

James T. Dalton - Lakeland TN, US
Shontelle Dodson - Naperville IL, US
Mitchell S. Steiner - Germantown TN, US

A61K 31/277, A61P 21/02

514522

This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC.

2004009, May 13, 2004

Jul 2, 2003

10/611056

Mitchell Steiner - Germantown TN, US
Sharan Raghow - Collierville TN, US

A61K031/137, A61K031/24

514/651000, 514/540000, 514/644000

This invention relates to methods of treating a subject with pre-malignant lesions of prostate cancer; and methods of suppressing, inhibiting or reducing the incidence of pre-malignant lesions of prostate cancer.

2006027, Dec 7, 2006

Jan 4, 2006

11/324753

James Dalton - Upper Arlington OH, US
Duane Miller - Germantown TN, US
Mitchell Steiner - Germantown TN, US
Karen Veverka - Cordova TN, US

A61K 31/277

514521000

This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.

2012007, Mar 29, 2012

Aug 23, 2011

13/215679

James T. DALTON - Lakeland TN, US
Mitchell S. STEINER - Germantown TN, US
Ronald A. MORTON - Memphis TN, US

A61K 31/137, A61P 5/26, A61K 31/4453, A61K 31/167, A61P 35/00

514331, 514622, 514617, 514655

The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.